Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Common Equity: 2017-2024

Historic Common Equity for Crinetics Pharmaceuticals (CRNX) over the last 8 years, with Dec 2024 value amounting to $1.3 billion.

  • Crinetics Pharmaceuticals' Common Equity rose 28.71% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year increase of 28.71%. This contributed to the annual value of $1.3 billion for FY2024, which is 145.74% up from last year.
  • Latest data reveals that Crinetics Pharmaceuticals reported Common Equity of $1.3 billion as of FY2024, which was up 145.74% from $539.1 million recorded in FY2023.
  • In the past 5 years, Crinetics Pharmaceuticals' Common Equity registered a high of $1.3 billion during FY2024, and its lowest value of $168.9 million during FY2020.
  • For the 3-year period, Crinetics Pharmaceuticals' Common Equity averaged around $726.7 million, with its median value being $539.1 million (2023).
  • As far as peak fluctuations go, Crinetics Pharmaceuticals' Common Equity decreased by 4.70% in 2022, and later skyrocketed by 145.74% in 2024.
  • Crinetics Pharmaceuticals' Common Equity (Yearly) stood at $168.9 million in 2020, then soared by 96.51% to $331.9 million in 2021, then fell by 4.70% to $316.3 million in 2022, then spiked by 70.43% to $539.1 million in 2023, then soared by 145.74% to $1.3 billion in 2024.